To evaluate the knockdown efficiency of the newly synthesized isiBCL-2 molecule, a transfection experiment was conducted in glioma cells, followed by the quantification of BCL-2 mRNA levels using RT-qPCR. This evidence concerns the gene BCL2 and central nervous system cancer.